1. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

antibody

" in MedChemExpress (MCE) Product Catalog:

2575

Inhibitors & Agonists

4

Screening Libraries

182

Fluorescent Dye

190

Biochemical Assay Reagents

54

Peptides

18

MCE Kits

1981

Inhibitory Antibodies

13

Natural
Products

2

Recombinant Proteins

3

Isotope-Labeled Compounds

3714

Antibodies

263

Click Chemistry

37

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99018

    antibody ANB 020

    Interleukin Related Cancer
    Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis .
    Etokimab
  • HY-P99289

    antibody hLL 2; Anti-Human CD22 Recombinant antibody

    CD22 Inflammation/Immunology Cancer
    Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
    Epratuzumab
  • HY-P990387

    Ser/Thr Protease Inflammation/Immunology
    The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CTSS/Cathepsin S Antibody (Fsn0503h)
  • HY-P990393

    CXCR Inflammation/Immunology
    Anti-CXCL9 Antibody is a humanized antibody expressed in CHO cells, targeting CXCL9. The Anti-CXCL9 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXCL9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CXCL9 Antibody
  • HY-P990541

    VEGFR Inflammation/Immunology
    Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-VEGFR1/FLT1 Antibody
  • HY-P990395

    CXCR Inflammation/Immunology
    Anti-CXCR4/CD184 Antibody is a CHO-expressed human antibody that targets CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CXCR4/CD184 Antibody
  • HY-P990392

    CXCR Inflammation/Immunology
    Anti-CXCL8/IL-8 Antibody is a human antibody expressed in CHO cells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CXCL8/IL-8 Antibody
  • HY-P990371

    IM-301

    HCV Inflammation/Immunology
    Anti-CLDN6 Antibody (IM-301) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (IM-301) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa.
    Anti-CLDN6 Antibody (IM-301)
  • HY-P990391

    CXCR Inflammation/Immunology
    The Anti-CXCL4/PF4 Antibody is a human antibody expressed in CHO cells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-CXCL4/PF4 Antibody
  • HY-P990542

    VEGFR Inflammation/Immunology
    Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-VEGFR2/KDR/CD309 Antibody
  • HY-P990369

    AB3-7

    HCV Inflammation/Immunology
    Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 78.02 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CLDN6 Antibody (AB3-7)
  • HY-P990368

    AB1-11

    HCV Inflammation/Immunology
    Anti-CLDN6 Antibody (AB1-11) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (AB1-11) has an IgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 78.42 kDa. The isotype control for Anti-CLDN6 Antibody (AB1-11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CLDN6 Antibody (AB1-11)
  • HY-P991041

    ADC Antibody Cancer
    Anti-SEZ6 Antibody (SC17) is an anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011 .
    Anti-SEZ6 Antibody (SC17)
  • HY-P990543

    VEGFR Inflammation/Immunology
    The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-VEGFR2/KDR/CD309 Antibody (AT001)
  • HY-P990394

    CXCR Inflammation/Immunology
    Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CXCR3/GPR9/CD183 Antibody
  • HY-P99352

    Anti-MSLN antibody

    Mesothelin Cancer
    Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .
    Anetumab
  • HY-P990579

    HCV Inflammation/Immunology
    DS-9606A is a humanized antibody expressed in CHO cells, targeting CLDN6. DS-9606A features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for DS-9606A can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CLDN6 Antibody (DS-9606A antibody)
  • HY-P99271

    Anti-Human F3 Recombinant antibody

    ADC Antibody Cancer
    Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors .
    Tisotumab
  • HY-P99296

    CNTO 95; Anti-Human CD51 Recombinant antibody

    EGFR Cancer
    Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .
    Intetumumab
  • HY-P99324

    Anti-Human EGFR Recombinant antibody

    EGFR Apoptosis Cancer
    Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
    Tomuzotuximab
  • HY-P99313

    Anti-Human IGHE Recombinant antibody

    Apoptosis Inflammation/Immunology
    Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
    Quilizumab
  • HY-P99292

    HuZAF; Anti-Human IFNG Recombinant antibody

    IFNAR Inflammation/Immunology
    Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
    Fontolizumab
  • HY-P99144A

    PD-1/PD-L1 Inflammation/Immunology
    Anti-Mouse PD-1 Antibody (S-5001) is an anti-mouse PD-1 IgG1 antibody inhibitor.
    Anti-Mouse PD-1 Antibody (S-5001)
  • HY-P99372

    Anti-NCAM1/ CD56 Reference antibody (lorvotuzumab)

    ADC Antibody Cancer
    Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
    Lorvotuzumab
  • HY-P99374

    Anti-TSPAN26/CD37 Reference antibody (naratuximab)

    ADC Antibody Cancer
    Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
    Naratuximab
  • HY-P99295

    RG 7160; RO 5083945; Anti-EGFR Recombinant antibody

    EGFR Cancer
    Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
    Imgatuzumab
  • HY-P99328

    Anti-EPCAM Recombinant antibody; huKS-IL2

    Interleukin Related Inflammation/Immunology Cancer
    Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
    Tucotuzumab
  • HY-P990107

    TGF-β Receptor Inflammation/Immunology
    Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) is an anti-mouse/human/rat/monkey/hamster/canine/bovine IgG antibody inhibitor of TGF-β . The recommend isotype control of Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8)
  • HY-P9916

    Anti-Human IL6Rα, Human antibody

    Interleukin Related Inflammation/Immunology Cancer
    Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis .
    Sarilumab
  • HY-P99269

    BIBH 1; Anti-Human FAP Recombinant antibody

    FAP Cancer
    Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
    Sibrotuzumab
  • HY-P9917
    Tocilizumab
    20+ Cited Publications

    Anti-Human IL6R, Humanized antibody

    Interleukin Related Inflammation/Immunology Cancer
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
    Tocilizumab
  • HY-P9914

    Anti-Human C5, Humanized antibody

    Complement System Cardiovascular Disease Cancer
    Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .
    Eculizumab
  • HY-P99330

    Anti-Human VEGFA Recombinant antibody; RO5520985

    VEGFR Tie Cancer
    Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
    Vanucizumab
  • HY-P99293

    IDEC 114; Anti-Human CD80 Recombinant antibody

    CD28 Cancer
    Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
    Galiximab
  • HY-P99263
    Inclacumab
    1 Publications Verification

    Anti-Human selectin P Recombinant antibody

    P-selectin Cardiovascular Disease
    Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
    Inclacumab
  • HY-P9915
    Daratumumab
    1 Publications Verification

    Anti-Human CD38, Human antibody

    CD38 ADC Antibody Inflammation/Immunology Cancer
    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
    Daratumumab
  • HY-P99315

    BG 9588; Anti-Human CD40L Recombinant antibody

    TNF Receptor Inflammation/Immunology
    Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .
    Ruplizumab
  • HY-P99275
    Patritumab
    1 Publications Verification

    Human Anti-ERBB3 Recombinant antibody

    EGFR Akt ERK PARP Survivin Cancer
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
    Patritumab
  • HY-P99270

    CS-1008; Anti-Human TRAIL-R2 Recombinant antibody

    Apoptosis Cancer
    Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
    Tigatuzumab
  • HY-P99288

    Pamrevlumab; Anti-Human CTGF Recombinant antibody

    Apoptosis Cancer
    FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
    FG-3019
  • HY-P99252

    Anti-Human CD6 Recombinant antibody

    CD6 Infection Inflammation/Immunology
    Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
    Itolizumab
  • HY-P99362

    Anti-MUC5AC Reference antibody (ensituximab); NEO-102

    Mucin Others Cancer
    Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .
    Ensituximab
  • HY-P99294

    AMG 479; Human Anti-IGF1R Recombinant antibody

    IGF-1R Cancer
    Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
    Ganitumab
  • HY-P99785

    HLX20

    PD-1/PD-L1 Cancer
    Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
    Opucolimab
  • HY-P99256

    SCH 900222; MK 3222; Anti-Human IL23 Recombinant antibody

    Interleukin Related Inflammation/Immunology Cancer
    Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
    Tildrakizumab
  • HY-P990055

    EGFR Cancer
    Nezutatug is an anti-HER3 antibody, and used for cancer research .
    Nezutatug
  • HY-P990335

    Others ANGPTL Inflammation/Immunology
    Anti-ANGPTL4 Antibody
  • HY-P990336

    Others ANGPTL Inflammation/Immunology
    Anti-ANGPTL8 Antibody
  • HY-P990833

    Others Mesothelin Others
    Anti-Mesothelin Antibody (YP218) is a kind of rabbit IgG chimeric antibody, targeting to human Mesothelin.
    Anti-Mesothelin Antibody (YP218)
  • HY-P99336

    BI-RR 0001; Anti-Human IL6 Recombinant antibody

    Integrin Neurological Disease Inflammation/Immunology
    Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
    Enlimomab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: